Novel Diagnosis and Therapy of Neurodegenerative Retinal Disease, from Bench to Bedside

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 1952

Special Issue Editors

Department of Psychology, Faculty of Social Sciences, The University of Hong Kong, Hong Kong, China
Interests: neuroprotection; retinal ganglion cell; glaucoma; Alzheimer’s disease; electrical stimulation
Tianjin Medical University Eye Hospital, Tianjin, China
Interests: glaucoma; cataract; inherited eye diseases; intraocular pressure; optic nerve

Special Issue Information

Dear Colleagues,

Neurodegenerative retinal disease includes a broad spectrum of phenotypes, and usually causes vision loss and affects patient quality of life. By 2050, there will be an estimated 114.6 million people suffering from blindness and 587.6 million people affected by moderate and severe vision impairment. It is also a public health concern in terms of potential economic and social burdens. Therefore, preventive strategies, early diagnosis, improving the understanding of the phenotypes, and the development of new therapies are the main challenges in the future management of this disease. Neuroprotection is one of the most promising approaches for degenerative diseases in the retina. Although there have been numerous efforts to establish neuroprotective therapies in animal models, there have only been a handful of successful attempts in human retina.

The aim of this Research Topic is to gather original research articles and reviews based on the current studies addressing recent advances in risk factors, disease mechanisms, diagnostic modalities, and therapeutic options in approaches in retinal degeneration (inherited retinal degenerative diseases, glaucoma, age-related macular degeneration, diabetic retinopathy, traumatic optic neuropathy, myopia, retinal degeneration in neurodegenerative diseases and others). Studies from both bench (basic science) and bedside (clinical research) are welcome. 

Potential topics include but are not limited to the following:

  • Diagnostic biomarkers such as ERG, VEP, visual field and tear components;
  • Imaging modalities such as OCT, OCTA;
  • Therapeutic options such as neuroprotective agents (neurotrophic factors, antioxidants, etc.), neuroimmune modulation;
  • Clinical phenotypes;
  • Genetic background and gene therapy.

Dr. Kin Chiu
Dr. Wei Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegenerative retinal disease
  • glaucoma
  • myopia
  • diabetic retinopathy
  • age-related macular degeneration
  • retinitis pigmentosa
  • inherited retinal degenerative diseases
  • optic neuropathy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 942 KiB  
Article
Diagnostic Capability of Isolated-Check Visual Evoked Potential for Early to Moderate Primary Open-Angle Glaucoma
by Xia Wang, Yuan Fang, Ruoshi Li and Yingzi Pan
Life 2023, 13(6), 1257; https://doi.org/10.3390/life13061257 - 25 May 2023
Viewed by 1211
Abstract
This study aimed to evaluate the diagnostic capability of isolated-check visual evoked potential (icVEP) for primary open-angle glaucoma (POAG) via comparison with visual field (VF) tests and pattern visual evoked potential (PVEP). This cross-sectional study enrolled 68 subjects, including 33 POAG patients and [...] Read more.
This study aimed to evaluate the diagnostic capability of isolated-check visual evoked potential (icVEP) for primary open-angle glaucoma (POAG) via comparison with visual field (VF) tests and pattern visual evoked potential (PVEP). This cross-sectional study enrolled 68 subjects, including 33 POAG patients and 35 controls. All subjects underwent a complete ophthalmic examination, including icVEP, PVEP, and VF tests. The diagnostic performance, the area under the receiver operating characteristic curve (AUC), the integrated discrimination index (IDI), and the net reclassification index (NRI) were calculated. The clinical benefits of the three tests were compared via decision curve analysis (DCA) of the signal-to-noise ratio (SNR) from icVEP, the P100 latency and amplitude of 1° and 0.25° checks from the PVEP, pattern standard deviation (PSD), and mean deviation (MD) from the VF test. The SNR, MD and PSD, PVEP P100 latency of 0.25° checks, and P100 amplitude (both 1° and 0.25° checks) showed significant differences between the POAG and control groups (* p < 0.05), except for the P100 latency of 1° checks. Regarding diagnostic ability, the three tests, AUC, IDI, and NRI, showed no significant difference (p > 0.05). The DCA showed that the clinical benefits of icVEP (SNR) were comparable to those of VF (MD and PSD) and better than those of PVEP (P100 latency and amplitude). In addition, no significant difference was found in the consistency analysis of the qualitative comparison between the icVEP, VF, and PVEP (McNemar p > 0.05). In this study, icVEP showed a diagnostic ability for early to moderate POAG patients comparable to VF and PVEP. IcVEP might be applied as a supplementary psychophysical examination method in addition to VF examinations for special POAG populations who have difficulty cooperating with the VF examination. Full article
Show Figures

Figure 1

Back to TopTop